Présentation de l'entreprise
VivoSim Labs, Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry, where it provides specialized services for testing drugs and drug candidates. The company distinguishes itself by utilizing three-dimensional (3D) human tissue models of the liver and intestine to offer partners critical liver and intestinal toxicology insights through its new approach methodologies (NAM) models. As of the latest data, the firm maintains a market capitalization of $4.57 million, generates annual revenue of $142,000, and employs a workforce of 14 individuals. These valuation and revenue figures indicate that VivoSim Labs is a micro-cap entity with a very small operational scale relative to the broader biotechnology market. The low market cap combined with minimal revenue suggests the company is in an early-stage development phase, likely prioritizing research and infrastructure expansion over immediate profitability. With such a limited number of employees and a market cap under $10 million, the company's position is that of a niche player dependent on successful partnerships to achieve significant scale.
Santé financière
The company reported a revenue of $142,000 for the trailing twelve months, while simultaneously recording a net income of -$1,227,000 and an EBITDA of -$11,221,000. The substantial negative gap between the minimal revenue of $142,000 and the net loss of $1,227,000 reveals a cost structure where operating expenses vastly outweigh current income-generating activities, a common characteristic of early-stage biotechnology firms. Free cash flow stands at -$7,895,875, indicating that the company is burning cash at a significant rate, which limits its financial flexibility and necessitates reliance on external capital sources such as equity financing or debt. Regarding profitability metrics, the gross margin is 0.0%, the operating margin is -10576.9%, and the profit margin is 0.0%; these figures collectively indicate that the company has not yet achieved operational breakeven and is incurring heavy costs relative to sales. The balance sheet shows $4.29 million in cash against $812,000 in debt, supported by a debt-to-equity ratio of 18.28, suggesting that while the company is currently net cash-positive, its capital structure relies heavily on equity rather than debt financing. The current ratio of 2.44 indicates that the company possesses sufficient current assets to cover its short-term liabilities, providing a layer of liquidity security despite the ongoing operational losses. Return on Equity is -51.1% and Return on Assets is -132.5%, metrics that reveal that management has not yet generated positive returns on the capital invested, reflecting the high-risk nature of the business model where losses are amplified by the asset base.
Évaluation de la valorisation
The valuation metrics present a complex picture, with a trailing P/E ratio of 0.90 and a forward P/E listed as N/A; the absence of a forward P/E implies that analysts cannot currently project positive earnings, meaning the expected earnings trajectory remains uncertain and potentially negative in the short term. The price-to-book ratio is 0.93, which indicates that the market values the company at approximately 93% of its book value, suggesting a lack of market premium over tangible assets and potentially a conservative or distressed valuation stance. Alternative valuation metrics further illustrate the company's financial reality, with a price-to-sales ratio of 32.21 and an EV/EBITDA of -0.06; these high multiples relative to sales combined with a negative EV/EBITDA suggest that the market is pricing in high expectations for future commercialization success despite current financial unprofitability. The stock has traded between a 52-week high of $5.30 and a 52-week low of $1.25, and without the specific current share price, the exact percentage deviation from these levels cannot be calculated, though the wide trading range of $4.05 reflects significant price volatility. The beta of 1.44 indicates that the stock is expected to be 44% more volatile than the broader market, meaning price movements will likely be amplified during periods of general market turbulence.
Growth & Income
Revenue growth for the year-over-year period stands at 8.3%, while earnings growth is N/A due to the company's negative earnings history; since earnings are negative, they are not growing in the traditional sense, but the stabilization of losses or path toward profitability is implied by the positive revenue trend. As a non-dividend payer, VivoSim Labs reports a dividend yield of N/A and a payout ratio of 0.0%, meaning the company retains all earnings to reinvest into research, development, and operational expansion rather than distributing income to shareholders. The absence of a dividend payout is consistent with the company's lifecycle stage, where capital retention is prioritized to fund the expensive processes of drug testing and tissue model development. Overall, the growth and income profile is characterized by positive revenue expansion coupled with significant cash burn and no dividend distribution, presenting a high-risk, high-potential-return scenario typical of pre-commercial biotechnology entities.